Eli Lilly's Efforts to Combat Weight-Loss Drug Misconceptions

Eli Lilly is launching a campaign to dispel misconceptions about weight-loss drugs and emphasize the importance of obesity treatment as a disease. The company's popular drugs, including Zepbound and Mounjaro, have seen increased demand, leading to availability issues. The FDA recently approved Lilly's drug tirzepatide for obesity treatment. The campaign aims to promote dialogue about the appropriate use of anti-obesity medications and address concerns about their use for cosmetic weight loss. Additionally, Lilly's launch of a website for direct home delivery of select medicines has raised concerns among medical professionals.